1034 related articles for article (PubMed ID: 25052475)
41. Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.
Boner G; Cooper ME; McCarroll K; Brenner BM; de Zeeuw D; Kowey PR; Shahinfar S; Dickson T; Crow RS; Parving HH;
Diabetologia; 2005 Oct; 48(10):1980-7. PubMed ID: 16082528
[TBL] [Abstract][Full Text] [Related]
42. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study.
Okin PM; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Lindholm LH; Dahlöf B;
Hypertension; 2007 Nov; 50(5):984-90. PubMed ID: 17893425
[TBL] [Abstract][Full Text] [Related]
43. Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study.
Bang CN; Soliman EZ; Simpson LM; Davis BR; Devereux RB; Okin PM;
Am J Hypertens; 2017 Sep; 30(9):914-922. PubMed ID: 28430947
[TBL] [Abstract][Full Text] [Related]
44. Prediction of stroke with electrocardiographic left ventricular hypertrophy in hypertensive patients: A meta-analysis.
Yi S; Wang F; Wan M; Yi X; Zhang Y; Sun S
J Electrocardiol; 2020; 61():27-31. PubMed ID: 32504899
[TBL] [Abstract][Full Text] [Related]
45. Variability and concordance of Cornell and Sokolow-Lyon electrocardiographic criteria in hypertensive patients.
Vinyoles E; Rodriguez-Blanco T; de la Figuera M; Colomé JM; Tafalla M; Calbet N; Fernández-San Martin MI; García-Alonso J; Murillo C; Agudo J
Blood Press; 2012 Dec; 21(6):352-9. PubMed ID: 22587668
[TBL] [Abstract][Full Text] [Related]
46. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
Devereux RB; Palmieri V; Liu JE; Wachtell K; Bella JN; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Dahlöf B
J Hypertens; 2002 Jul; 20(7):1445-50. PubMed ID: 12131543
[TBL] [Abstract][Full Text] [Related]
47. Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study.
de Simone G; Olsen MH; Wachtell K; Hille DA; Dahlöf B; Ibsen H; Kjeldsen SE; Lyle PA; Devereux RB
J Hum Hypertens; 2007 Aug; 21(8):625-32. PubMed ID: 17476291
[TBL] [Abstract][Full Text] [Related]
48. Standard electrocardiographic criteria for left ventricular hypertrophy in Nigerian hypertensives.
Dada A; Adebiyi AA; Aje A; Oladapo OO; Falase AO
Ethn Dis; 2005; 15(4):578-84. PubMed ID: 16259479
[TBL] [Abstract][Full Text] [Related]
49. Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint study.
Bang CN; Okin PM; Køber L; Wachtell K; Gottlieb AB; Devereux RB
J Hypertens; 2014 Mar; 32(3):667-72. PubMed ID: 24379001
[TBL] [Abstract][Full Text] [Related]
50. Prognostic significance of left ventricular mass change during treatment of hypertension.
Devereux RB; Wachtell K; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris K; Aurup P; Dahlöf B
JAMA; 2004 Nov; 292(19):2350-6. PubMed ID: 15547162
[TBL] [Abstract][Full Text] [Related]
51. Relationship of diastolic function to new or persistent electrocardiographic left ventricular hypertrophy.
Tanoue MT; Kjeldsen SE; Devereux RB; Okin PM
Blood Press; 2016 Dec; 25(6):364-372. PubMed ID: 27146272
[TBL] [Abstract][Full Text] [Related]
52. Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Ruwald AC; Westergaard B; Sehestedt T; Kjeldsen SE; Lindholm LH; Wachtell K; Devereux RB; Ibsen H; Nieminen MS; Dahlöf B; Olsen MH
J Hypertens; 2012 Jun; 30(6):1252-9. PubMed ID: 22499288
[TBL] [Abstract][Full Text] [Related]
53. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.
Dahlöf B; Devereux RB; Julius S; Kjeldsen SE; Beevers G; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
Hypertension; 1998 Dec; 32(6):989-97. PubMed ID: 9856962
[TBL] [Abstract][Full Text] [Related]
54. Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.
Okin PM; Wright JT; Nieminen MS; Jern S; Taylor AL; Phillips R; Papademetriou V; Clark LT; Ofili EO; Randall OS; Oikarinen L; Viitasalo M; Toivonen L; Julius S; Dahlöf B; Devereux RB
Am J Hypertens; 2002 Aug; 15(8):663-71. PubMed ID: 12160187
[TBL] [Abstract][Full Text] [Related]
55. Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study.
Ariansen I; Reims HM; Gjesdal K; Olsen MH; Ibsen H; Devereux RB; Okin PM; Kjeldsen SE; Dahlöf B; Wachtell K
Blood Press; 2012 Feb; 21(1):6-11. PubMed ID: 22070095
[TBL] [Abstract][Full Text] [Related]
56. Obesity and ECG left ventricular hypertrophy.
Muiesan ML; Salvetti M; Di Castelnuovo A; Paini A; Assanelli D; Costanzo S; Badilini F; Vaglio M; Donati MB; Agabiti Rosei E; de Gaetano G; Iacoviello L;
J Hypertens; 2017 Jan; 35(1):162-169. PubMed ID: 27662187
[TBL] [Abstract][Full Text] [Related]
57. Impact of achieved systolic blood pressure on renal function in hypertensive patients.
Okin PM; Kjeldsen SE; Devereux RB
Eur Heart J Qual Care Clin Outcomes; 2016 Oct; 2(4):271-276. PubMed ID: 29474712
[TBL] [Abstract][Full Text] [Related]
58. Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudy.
Olsen MH; Wachtell K; Ibsen H; Lindholm L; Kjeldsen SE; Omvik P; Nieminen MS; Dahlöf B; Okin PM; Devereux RB
J Hypertens; 2011 May; 29(5):997-1004. PubMed ID: 21358415
[TBL] [Abstract][Full Text] [Related]
59. Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy.
Okin PM; Bang CN; Wachtell K; Hille DA; Kjeldsen SE; Dahlöf B; Devereux RB
Circ Arrhythm Electrophysiol; 2013 Apr; 6(2):243-51. PubMed ID: 23403268
[TBL] [Abstract][Full Text] [Related]
60. Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study.
Boman K; Gerdts E; Wachtell K; Dahlöf B; Nieminen MS; Olofsson M; Papademetriou V; Devereux RB
Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):242-8. PubMed ID: 19369828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
